DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced the appointment of two renowned experts to its Scientific Advisory Board (“SAB”). Dr. Marilyn Ritholz, psychologist at Joslin Diabetes Center, a Harvard Medical School affiliate, and Dr. David Horwitz, former global chief medical officer of Johnson & Johnson Diabetes Institute, join SAB chairman Eric Milledge; the prestigious board is focused on advancing Dario’s technical leadership, helping to guide the development of the company’s bold technology road map and advancing Dario’s DTx (“DTx”) platform by integrating members’ comprehensive experience and expertise into the company offering. Ritholz and Horwitz are recognized as experts in the fields of diabetes, metabolism, and behavioral health. A senior psychologist at the Joslin Diabetes Center, Ritholz is also on the faculty at Beth Israel Deaconess Medical Center (“BIDMC”) and is an assistant professor of psychology at Harvard Medical School. A senior consultant with Numerof & Associates, Horwitz also serves as president of DLH Biomedical Consulting and has previously held faculty positions in the medical schools at the University of Chicago and the University of Illinois. “My objective is to populate Dario’s SAB with renowned members of the global medical community who align with Dario’s approach to empower individuals to achieve meaningful, sustainable behavior change through highly personalized, AI-driven experiences that adapt dynamically through a member’s journey,” said Milledge in the press release. “Dr. Ritholz’s accomplishments at the Joslin Diabetes Center, a Harvard Medical School affiliate, include a leading practice focused on the intersection of psychology and diabetes management in adolescents and adults. Her expertise will be key in refining aspects of our technology for improved patient-provider interactions and, ultimately, better care. Dr. Horwitz’s experiences as a Board-Certified internist and endocrinologist, coupled with his knowledge of the healthcare ecosystem, will lay the foundation for a strong board committed to improving patient care. I am excited to work with them as we continue to build out the SAB and drive continued innovation of Dario’s platform.”
To view the full press release, visit https://ibn.fm/0jsJu
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software and coaching, the company makes the right thing to do the easy thing to do. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The highly engaging, user-centric MyDario(TM) mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork